04/13/2018 | Press release | Distributed by Public on 04/13/2018 09:58
EDMONTON, ALBERTA - April 13, 2018 - Ceapro Inc. (TSX-V: CZO) ('Ceapro' or the 'Company'), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that it will present at the 12th International Symposium on Supercritical Fluids (ISSF 2018) being held April 22-25, 2018 in Antibes, France.
Bernhard Seifried, Ph.D., Ceapro's Director of Engineering Research and Technology, and Feral Temelli, Ph.D., from the Department of Agricultural, Food & Nutritional Science of the University of Alberta will present the case study titled, 'PGX Technology: A Case of University - Industry Partnership for Innovation,' in an oral presentation on Wednesday April 25, 2018 at 9:00 a.m. CEST.
As part of the presentation, Drs. Seifried and Temelli will discuss Ceapro's patented Pressurized Gas eXpanded ('PGX') platform technology that is used to convert biopolymers into high-value materials overcoming the challenges associated with the drying of high molecular weight biopolymers using conventional technologies, and the supercritical fluid technology research program of Dr. Temelli at the University of Alberta.
Following the presentation, a comprehensive article will be included in the conference proceedings and will be available on Ceapro's website (www.ceapro.com).
About Pressurized Gas eXpanded Liquid Technology (PGX)
The Company's patented Pressurized Gas eXpanded (PGX) is a unique and disruptive technology with several key advantages over conventional drying and purification technologies that can be used to process biopolymers into high-value, nano-sized polymer structures and novel bio-nanocomposites. PGX is ideally suited for processing challenging high-molecular weight, water-soluble biopolymers. It has the ability to make ultra-light, highly porous polymer structures on a continuous basis, which is not possible using today's conventional technologies. PGX was invented by Dr. Feral Temelli from the Department of Agricultural, Food & Nutritional Science of the University of Alberta (U of A) along with Dr. Bernhard Seifried, now Ceapro's Director of Engineering Research and Technology. The license from U of A provides Ceapro with exclusive worldwide rights in all industrial applications.
About Ceapro Inc.
Ceapro Inc. is a Canadian biotechnology company involved in the development of proprietary extraction technology and the application of this technology to the production of extracts and 'active ingredients' from oats and other renewable plant resources. Ceapro adds further value to its extracts by supporting their use in cosmeceutical, nutraceutical, and therapeutics products for humans and animals. The Company has a broad range of expertise in natural product chemistry, microbiology, biochemistry, immunology and process engineering. These skills merge in the fields of active ingredients, biopharmaceuticals and drug-delivery solutions. For more information on Ceapro, please visit the Company's website at www.ceapro.com.
For more information contact:
Jenene Thomas Communications, LLC
Investor Relations and Corporate Communications Advisor
T (US): +1 (833) 475-8247
E: [email protected]
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.